CPRX News and Press, Catalyst Pharmaceuticals Inc. From 01/17/24

2024-01-17 14:13:32 ET Summary Catalyst Pharmaceuticals, Inc. has one approved product and another about to be launched, but its market cap is low at $1.7bn. The company is facing a major patent challenge and has high expenses with no major data catalysts or pipeline molecules. ...

2024-01-15 08:45:00 ET Biotech stocks tend to be a lot riskier than your average investment. But if you buy a basket of biotechs today and hold onto them for long enough, the balance of risk and reward should be tilted in your favor. Let's examine three companies suitable for such a strateg...

2024-01-14 08:40:00 ET It's fully possible that the meme coin Shiba Inu (CRYPTO: SHIB) could go on a bull run this year as cryptocurrencies start to recover with gusto from the bear market. But for those seeking an investment in an asset that'll actually grow sustainably in value ov...

CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares o...

2024-01-07 03:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 08:23:53 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Earnings Call Transcript Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity Catalyst Pharmaceuticals stock sinks on proposed public of...

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.0...

2024-01-04 16:56:43 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Earnings Call Transcript Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity Catalyst Pharmaceuticals appoints Kalb as its CFO ...

CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today ...

CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100...